

Haematologica  
HAEMATOL/2017/181297  
Version 3

Benefits and pitfalls of Peg-Interferon- $\alpha$ 2a therapy in patients with  
myeloproliferative neoplasm-associated myelofibrosis, a French  
Intergroup of Myeloproliferative neoplasms (FIM) study

Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard,  
Emmanuel Gyan, Kamel Laribi, Pascale Cony-Makhoul, Jean-Loup  
Demory, Benoit de Renzis, Christine Dosquet, Jerome Rey, Lydia Roy,  
Brigitte Dupriez, Laurent Knoops, Laurence Legros, Mohamed Malou,  
Pascal Hutin, Dana Ranta, Omar Benbrahim, Valérie Ugo, Eric Lippert,  
and Jean-Jacques Kiladjian

Disclosures: JCI received a grant from Novartis; JJK received personal fees and non-financial supports from Novartis and Shire, and grants from AOP Orphan. The other authors declared to have no conflict of interest.

Contributions: JCI, EL and JJK designed and performed the study and analyzed the data; JCI, FBP, EG, KL, PCM, JLD, BD, CD, JR, LR, BD, LK, LL, MM, PH, DR, OB and JJK collected the data; AC, EL and VU performed the molecular analyses; and all authors gave final approval of the manuscript.